Latest Headlines

1. CN Bio And Pharmaron Establish Long-Term Strategic Partnership To Develop OOC Technologies On A Global R&D Platform 4/23/2025

   CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry.

2. Charles River Leverages Advanced Technology To Expedite Oncology Drug Discovery And Development 4/22/2025

   Charles River Laboratories International, Inc., ahead of the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive portfolio of products and services supporting the discovery and development of novel oncology drugs.

3. TNF Pharmaceuticals And Renova Health Utilize AI To Accelerate Drug Development 4/22/2025

   TNF Pharmaceuticals, Inc. (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.

4. Argonne Leverages AI And Supercomputing To Revolutionize Cancer Research 4/22/2025

   Discovering new drugs to treat cancer and predicting how tumors will respond to them remain key challenges in the fight against the disease.

5. CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License From Chinese NMPA 4/22/2025

   CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company is pleased to announce that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China’s National Medical Products Administration (NMPA).

6. UT Health San Antonio-Led Discovery Means IV Medication Could Be Taken Orally For Range Of Cancer, Alzheimer's Treatments 4/21/2025

   A research team led by scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) made a major breakthrough with the potential to turn IV drugs into oral treatments for diseases like brain cancer and Alzheimer’s disease.

7. Viatris Files Supplemental New Drug Applications To Japan's Ministry Of Health, Labor And Welfare For The Approval Of EFFEXOR® For The Treatment Of Generalized Anxiety Disorder 4/21/2025

   Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has filed applications to the Ministry of Health, Labor and Welfare (MHLW) for approval of Effexor SR Capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI) to treat adults with generalized anxiety disorder (GAD), an indication for which no other treatment option is currently approved in Japan.

8. Kelun-Biotech's Novel ADC Drug SKB518 Has Been Granted The Clearance Of IND From The United States Food And Drug Administration (FDA) 4/21/2025

   Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study of its potential first-in-class innovative ADC drug SKB518 from the United States Food and Drug Administration (FDA).

9. Redwire Expands In-Space Drug Development Program, Launches New PIL-BOX Technology And Cancer-Detection Experiment 4/21/2025

   Redwire Corporation, a leader in space infrastructure for the next-generation space economy, announced today that it has launched a new drug development technology and a cancer-detection experiment to the International Space Station (ISS) as the company scales its in-space pharmaceutical drug development program based on the success of its PIL-BOX platform.

10. Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors 4/21/2025

    Zai Lab Limited today announced that China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.